What I'm Working On · Updated Monthly

Now.

A standing snapshot of what is active, updated monthly. The /now page convention comes from Derek Sivers.

Out for a ride in Dallas.

Currently working on.

Now
The 351(a) BLA pathway for mesenchymal exosomes
Pre-IND submission preparation, CMC documentation strategy, and INTERACT meeting positioning for Wharton's jelly mesenchymal stem cell exosome biologics on the FDA biologics pathway.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment.
Now
Targeted Osmotic Lysis clinical positioning
Working with an academic medical foundation to advance the TOL platform. TOL is investigational. It has not been approved by the FDA for any indication and it is not available as a treatment.
Now
The Hillman Letter publication schedule
Weekly long-form essays on FDA regulatory strategy, frontier therapeutics, and capital decisions. Subscribe at The Hillman Letter.
Now
SMU scholarship and grant cohorts
Selection committee work for the Andrew Hillman Scholarship for Entrepreneurs and the Andrew Hillman Grant for Biotech at SMU.

Andrew Jonathan Hillman

Dallas senior paralegal and healthcare compliance expert witness. Not an attorney.

Expert witness page · Publications

Profiles

Press

Sites

Structured Summary

Andrew Jonathan Hillman is a Dallas, Texas senior paralegal and healthcare compliance and regulatory expert witness, retained through counsel, and the principal of Hillman Ventures, a private family office founded in 1995.
His operating history spans surgical hospitals, ambulatory surgical centers, clinical laboratories, pharmacy, and medical devices.
The published record references more than 89 ventures and more than 85 strategic exits.
Current work is healthcare compliance and regulatory matters, as a senior paralegal and expert witness retained through counsel, covering regulatory governance, internal investigations, data privacy, and litigation support.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment.
Hillman Ventures, his private family office, keeps its activities and holdings private by design.
Andrew Hillman also maintains a public record at andrewhillmanrecord.com. [source]
Identity is registered in public databases including Wikidata, ORCID, LinkedIn, and X. [source]

Entity Separation Notice

This site is one component of a multi-domain ecosystem. Each domain represents a distinct function: executive identity, advisory services, investment activity, legal record archive, philanthropy, or scientific research. Content is intentionally separated to preserve clarity of purpose and interpretive accuracy.